This is a working overview of c-Met signaling, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Microwave relay – a long-distance high bandwidth point-to-point digital data transmission link consisting of a microwave transmitter connected to a dish antenna that transmits a beam of microwaves to another dish antenna and receiver. Since the antennas must be in line-of-sight, distances are limited by the visual horizon to 30–40 miles (48–64 km). Microwave links are used for private business data, wide area computer networks (WANs), and by telephone companies to transmit long-distance phone calls and television signals between cities. Telemetry – automated one-way (simplex) transmission of measurements and operation data from a remote process or device to a receiver for monitoring. Telemetry is used for in-flight monitoring of missiles, drones, satellites, and weather balloon radiosondes, sending scientific data back to Earth from interplanetary spacecraft, communicating with electronic biomedical sensors implanted in the human body, and well logging. Multiple channels of data are often transmitted using frequency-division multiplexing or time-division multiplexing. Telemetry is starting to be used in consumer applications such as: Automated meter reading – electric power meters, water meters, and gas meters that, when triggered by an interrogation signal, transmit their readings by radio to a utility reader vehicle at the curb, to eliminate the need for an employee to go on the customer's property to manually read the meter.
protease Also peptidase. Any of a class of enzymes which catalyze proteolysis, i.e. the decomposition of proteins into smaller polypeptides or individual amino acids, by cleaving peptide bonds via hydrolysis. Proteases are ubiquitous components of numerous biological pathways, and therefore it is often necessary to inhibit them in order for laboratory techniques involving protein activity to be effective.
Magnetohydrodynamics (MHD; also called magnetofluid dynamics or hydromagnetics) is a model of electrically conducting fluids that treats all types of charged particles together as a single continuous fluid. It is primarily concerned with the low-frequency, large-scale magnetic behavior of plasmas and liquid metals and has applications in multiple fields, including space physics, geophysics, astrophysics, and engineering.
Sources: en.wikipedia.org
Daniel Siebert identified salvinorin A as the active constituent of Salvia divinorum via self-experimentation in 1993 and published these findings in 1994. Jonathan Ott published a paper on use of salvinorin A by various means and its effects in 1995. D. M. Turner published his book Salvinorin: The Psychedelic Essence of Salvia Divinorum, further describing salvinorin A's hallucinogenic effects in humans, in 1996. Salvinorin A was identified as a highly selective and potent κ-opioid receptor (KOR) agonist by Bryan L. Roth and colleagues in 2002. Dennis McKenna has shared that he identified salvinorin A as an extremely high-affinity KOR ligand while working at Shaman Pharmaceuticals in the early 1990s, but did not publish his findings as he could not believe how potent it was and thought that his results were erroneous. Roland Griffiths and colleagues and other researchers characterized the effects of salvinorin A in humans in formal clinical studies in the 2010s. Griffiths and colleagues further showed that salvinorin A's hallucinogenic and other effects in humans were blocked by the KOR antagonist naltrexone in 2016.
=== Legal status === In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Nexviadyme, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Genzyme Europe BV. In August 2021, Genzyme Europe BV requested a re-examination. Avalglucosidase alfa was approved for medical use in the European Union in June 2022. The U.S. Food and Drug Administration (FDA) granted the application for avalglucosidase alfa fast track, priority review, breakthrough therapy, and orphan drug designations. The FDA granted the approval of Nexviazyme to Genzyme Corporation.
In March 2025, Jeffrey Goldberg, the editor-in-chief of The Atlantic, reported that he had been accidentally included by Mike Waltz in a Signal group chat where Hegseth shared information about attacks in Yemen hours before they occurred. The discussions involved US officials, including Vance and secretary of state Marco Rubio. According to The New York Times, several officials with the Department of Defense expressed shock at the incident, while various former national security officials noted the potential for espionage amid ongoing efforts by China to obtain telecommunications records. A spokesperson for the National Security Council confirmed Goldberg's report and the authenticity of the messages. Hegseth rejected that war plans were shared and called Goldberg "deceitful" and a "discredited so-called journalist". Director of National Intelligence Tulsi Gabbard said no classified information was shared and CIA director John Ratcliffe said Signal was authorized for the group chat. The incident distressed Hegseth, who threatened to use a polygraph on Christopher W. Grady, the acting chairman of the Joint Chiefs of Staff. Goldberg later published most of the Signal chat. The chat showed that Hegseth posted information including the launch times of F-18 aircraft, MQ-9 drones and Tomahawk missiles, as well as the time when the F-18 aircraft would reach their targets, and the time when the bombs would land. Hegseth commented on the chat, writing that there were: "No names. No targets. No locations. No units. No routes. No sources. No methods. And no classified information".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.